A Phase 3b, Multicenter, Open-label Exploratory Trial to Evaluate the Efficacy, Safety, and Subject Satisfaction With Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

Trial Profile

A Phase 3b, Multicenter, Open-label Exploratory Trial to Evaluate the Efficacy, Safety, and Subject Satisfaction With Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2016

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 26 Oct 2016 Results assessing efficacy and safety published in the International Journal of Neuropsychopharmacology.
    • 20 Sep 2016 Results from this and other two open label studies ( profiles 240013 and 240179), presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
    • 22 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top